Eyenovia, Inc. Stock News

Eyenovia said on Friday it would terminate a late-stage study testing its experimental drug-device combination for pediatric progressive myopia as it failed to meet the main goal.

A review of study data by an independent Data Review Committee found that CHAPERONE is not meeting its primary three-year efficacy endpoint

Eyenovia, Inc. (NASDAQ:EYEN ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Eric Ribner - IR Michael Rowe - CEO Bren Kern - COO Andy Jones - CFO Conference Call Participants Matthew Caufield - H.C. Wainwright Matt Kaplan - Ladenburg Thalmann Lachlan Hanbury-Brown - William Blair Kemp Dolliver - Brookline Capital Markets Len Yaffe - Stoc Doc Partners Operator...

Company to host an investor conference call and webcast at 4:30pm EDT Company to host an investor conference call and webcast at 4:30pm EDT

Presentation details efficacy and tolerability results from the successful Phase 3 program that led to FDA approval of clobetasol propionate suspension 0.05% for pain and inflammation following ocular surgery Presentation details efficacy and tolerability results from the successful Phase 3 program that led to FDA approval of clobetasol propionate suspension 0.05% for pain and inflammation foll...

The Gen-2 Optejet is designed for an optimized user experience while ensuring extended patent protection for products using the platform through 2041 The Gen-2 Optejet is designed for an optimized user experience while ensuring extended patent protection for products using the platform through 2041

NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company with two FDA-approved products and a late-stage asset in development for the treatment of pediatric progressive myopia, today announced it has entered into a securities purchase agreement with a healthcare focused institutional investor for the purchase and ...

New market research shows strong interest from ophthalmic surgeons following their review of Clobetasol's prescribing information New market research shows strong interest from ophthalmic surgeons following their review of Clobetasol's prescribing information